Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, priced at $10, below the original proposed range of $14-$16. The company planned to offer 4.5 million shares. The stock is expected to begin trading on the NASDAQ...read more
Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, revised the terms for its IPO on Wednesday. The Louisville, CO based company is now offering 4.5 million shares at $10. The company initially planned to offer 5...read more
Replidyne, a biopharmaceutical company developing a new class of antibiotics in collaboration with Forest Laboratories, announced the terms for its IPO on Tuesday. According to an amended SEC filing, the Louisville, CO based company plans to offer 5 million...read more
Replidyne, a biopharmaceutical company that develops innovative anti-infective products, registered for an initial public offering Wednesday evening. Merrill Lynch and Morgan Stanley are the joint book runners on the deal. Terms and timing have yet to be...read more
Biopharmaceutical firm Replidyne prices at $10
Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, priced at $10, below the original proposed range of $14-$16. The company planned to offer 4.5 million shares. The stock is expected to begin trading on the NASDAQ...read more
Biopharmaceutical firm Replidyne revises terms for its IPO
Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, revised the terms for its IPO on Wednesday. The Louisville, CO based company is now offering 4.5 million shares at $10. The company initially planned to offer 5...read more
Biopharmaceutical firm Replidyne announces terms for its IPO
Replidyne, a biopharmaceutical company developing a new class of antibiotics in collaboration with Forest Laboratories, announced the terms for its IPO on Tuesday. According to an amended SEC filing, the Louisville, CO based company plans to offer 5 million...read more
Biotech Replidyne files for IPO
Replidyne, a biopharmaceutical company that develops innovative anti-infective products, registered for an initial public offering Wednesday evening. Merrill Lynch and Morgan Stanley are the joint book runners on the deal. Terms and timing have yet to be...read more